From Inpatient to Outpatient: Practical Strategies for Optimizing Treatment of Hyperglycemia and Type 2 Diabetes Mellitus CME

Bruce W. Bode, MD; Stephen N. Davis, MD; Anthony P. Furnary, MD; Silvio E. Inzucchi, MD; John L. Leahy, MD Author Information and Disclosures

Release Date: March 7, 2008; Valid for credit through March 8, 2009

Credits Available
Physicians - maximum of 2.0 AMA PRA Category 1 Credit(s)™ for physicians

This activity, "From Inpatient to Outpatient: Practical Strategies for Optimizing Treatment of Hyperglycemia and Type 2 Diabetes Mellitus," is derived from the proceedings of 2 CME-accredited symposia held at the 67th Scientific Sessions of the American Diabetes Association in Chicago, Illinois, which took place on June 23 and June 24, 2007.

To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and complete the evaluation; (4) view/print certificate View details

Legal Disclaimer

The material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

  
Sanofi Aventis
Learning Objectives
Upon completion of this activity, participants should be able to:
  1. Analyze data supportive of intensive glucose control in hospitalized patients.
  2. Discuss different strategies for managing hyperglycemia and diabetes in both critically ill and non-critically ill inpatients.
  3. Discuss the progression of beta-cell degeneration during type 2 diabetes and its physiologic consequences.
  4. Understand the importance of both basal and postprandial glycemic control for overall glucose homeostasis in type 2 diabetes.
Authors and Disclosures

Bruce W. Bode, MD
Disclosure: Advisory board, consultant: Novo Nordisk; sanofi-aventis; Grant recipient, speaker's bureau: Eli Lilly and Company; Novo Nordisk; sanofi-aventis; Shareholder: GlucoTel


Stephen N. Davis, MD
Disclosure: Financial interest/arrangement or affiliation: Bayer Pharmaceuticals Corporation; Eli Lilly and Company; King Pharmaceuticals, Inc.; sanofi-aventis


Anthony P. Furnary, MD
Disclosure: Consultant: Edwards Lifesciences; GlucoLight; GluMetrics; LifeScan; Medtronic; Grant recipient: LifeScan; sanofi-aventis


Silvio E. Inzucchi, MD
Disclosure: Grant recipient: Eli Lilly and Company


John L. Leahy, MD
Disclosure: Consultant, speaker's bureau: Merck & Co.; sanofi-aventis
 
University of Cincinnati
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the University of Cincinnati and The Exeter Group. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.

The University of Cincinnati designates this educational activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Contact This Provider

All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.